Milind Deshpande

Milind Deshpande, PhD, is a Venture Partner at RA Capital since 2018.  During his tenure at RA Capital, Milind co-founded and built four companies and served as founding CEO and Board member.  He is also a Board member of Spero Therapeutics.  He was The Chairman of Board of Spero Therapeutics from its inception in 2014 until October 2023 and was integral to building the company. Milind is an accomplished drug hunter and inventor of three FDA approved first-in-class therapies.  Milind has over 30 years of experience in biotech and Pharma.  He was a Group Leader at Bristol-Myers Squibb with the responsibility for advancing the early discovery portfolio in Infectious Diseases and Neuroscience.  Following his tenure at BMS, Milind joined Achillion Pharmaceuticals (acquired by Alexion Pharmaceuticals) where he rose through the ranks to become the CEO and Board member